Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.Jun Ma, Jibin Li, Liangfang Shen et al.|Journal of Clinical Oncology|2024Cited by 17
PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.Jun Ma, Jibin Li, Ying Sun et al.|Journal of Clinical Oncology|2024Cited by 2